Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments-Reference-Cited by-同舟云学术

Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments

Published:2016-10-27 Issue:11 Volume:68 Page:2612-2617
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Xie Fenglong¹,Yun Huifeng¹,Bernatsky Sasha²,Curtis Jeffrey R.¹

Affiliation:

1. University of Alabama at Birmingham

2. McGill University; Montreal Quebec Canada

Funder

Drug Safety and Effectiveness Network

Canadian Institutes of Health Research

Patient Centered Outcomes Research Institute and the NIH

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Reference15 articles.

1. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants;Lanas;Clin Gastroenterol Hepatol,2015

2. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review;Gout;Clin Rheumatol,2011

3. The incidence of gastrointestinal perforations among rheumatoid arthritis patients;Curtis;Arthritis Rheum,2011

4. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use;Laine;Gastroenterology,2003

5. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations;Lanas;Gut,2006

Cited by 140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pneumomediastinum and pneumoretroperitoneum after COVID-19: concealed intestinal perforation;BMC Infectious Diseases;2024-08-08

2. Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome With Tofacitinib: A Case Report;Cureus;2024-08-05

3. Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment;Annals of the Rheumatic Diseases;2024-07-02

4. Risk of Gastrointestinal Perforation in Patients With Rheumatic Diseases Exposed to Janus Kinase Inhibitors Versus Adalimumab: A Nationwide Cohort Study;Arthritis & Rheumatology;2024-05-30

5. A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis;Expert Opinion on Drug Safety;2024-05-23